These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 30150994)

  • 1. Nanowires engineer naive T cells for immunotherapy.
    Slavkovic-Lukic D; Gattinoni L
    Nat Nanotechnol; 2024 Aug; 19(8):1085-1086. PubMed ID: 38802668
    [No Abstract]   [Full Text] [Related]  

  • 2. The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers.
    Cui C; Yu B; Jiang Q; Li X; Shi K; Yang Z
    Clin Exp Pharmacol Physiol; 2019 Jan; 46(1):3-10. PubMed ID: 30161295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers.
    Tsao SY
    Explor Target Antitumor Ther; 2022; 3(5):676-693. PubMed ID: 36338522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?
    Eleftheriadis T
    Front Immunol; 2018; 9():1879. PubMed ID: 30150994
    [No Abstract]   [Full Text] [Related]  

  • 5. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
    Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
    Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
    Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
    Front Immunol; 2022; 13():807271. PubMed ID: 35173722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marrying immunotherapy with chemotherapy: why say IDO?
    Muller AJ; Prendergast GC
    Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
    Cheong JE; Sun L
    Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.
    Brochez L; Kruse V; Schadendorf D; Muller AJ; Prendergast GC
    Front Immunol; 2021; 12():789473. PubMed ID: 34938297
    [No Abstract]   [Full Text] [Related]  

  • 10. Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer.
    Heeren AM; van Dijk I; Berry DRAI; Khelil M; Ferns D; Kole J; Musters RJP; Thijssen VL; Mom CH; Kenter GG; Bleeker MCG; de Gruijl TD; Jordanova ES
    Front Immunol; 2018; 9():1598. PubMed ID: 30050535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of metabolism by p53 - Cancer and beyond.
    Labuschagne CF; Zani F; Vousden KH
    Biochim Biophys Acta Rev Cancer; 2018 Aug; 1870(1):32-42. PubMed ID: 29883595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new cancer immunotherapy suffers a setback.
    Garber K
    Science; 2018 May; 360(6389):588. PubMed ID: 29748264
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.